Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis

被引：0
|
作者：
Mueller, J. [1 ,2 ,3 ]
Schaedelin, S. [4 ]
Benkert, P. [4 ]
Haenni, P. [5 ]
Schmid, J. [5 ]
Derfuss, T. [1 ,2 ,3 ]
Kuhle, J. [1 ,2 ,3 ]
Yaldizli, O. [1 ,2 ,3 ]
机构：
[1] Univ Hosp Basel, MS Ctr, Neurol Clin & Policlin, Basel, Switzerland
[2] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[3] Univ Basel, Basel, Switzerland
[4] Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland
[5] Swiss Federat Common Tasks Hlth Insurances SVK, Solothurn, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P819
引用
收藏
页码：676 / 676
页数：1
相关论文
共 50 条
  • [21] Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis
    Chan, Andrew
    de Seze, Jerome
    Comabella, Manuel
    CNS DRUGS, 2016, 30 (01) : 41 - 51
  • [22] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Xinke Zhang
    Joel W. Hay
    Xiaoli Niu
    CNS Drugs, 2015, 29 : 71 - 81
  • [23] Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis
    Papadopoulou, Athina
    Kappos, Ludwig
    Sprenger, Till
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 749 - 759
  • [24] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Zhang, Xinke
    Hay, Joel W.
    Niu, Xiaoli
    CNS DRUGS, 2015, 29 (01) : 71 - 81
  • [25] Dimethyl fumarate withdrawalFulminant rebound of relapsing-remitting multiple sclerosis: case report
    Reactions Weekly, 2018, 1711 (1) : 108 - 108
  • [26] Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Celeste B. Burness
    Emma D. Deeks
    CNS Drugs, 2014, 28 : 373 - 387
  • [27] Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Burness, Celeste B.
    Deeks, Emma D.
    CNS DRUGS, 2014, 28 (04) : 373 - 387
  • [28] Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
    Boullosa-Lale, Silvia
    Gonzalez-Freire, Lara
    Martinez-Martinez, Luciano
    Crespo-Diz, Carlos
    FARMACIA HOSPITALARIA, 2021, 45 (02) : 73 - 76
  • [29] COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Puma, E.
    Santoni, L.
    Prosperini, L.
    VALUE IN HEALTH, 2019, 22 : S740 - S741
  • [30] Dimethyl Fumarate or Teriflunomide for Relapsing–Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies
    Luca Prosperini
    Shalom Haggiag
    Serena Ruggieri
    Carla Tortorella
    Claudio Gasperini
    Neurotherapeutics, 2023, 20 : 1275 - 1283
12345